Core Viewpoint - Zhonghui Biotech-B (02627) shares rose over 7% following the announcement of the approval of its IND application for a recombinant respiratory syncytial virus vaccine by both the National Medical Products Administration (NMPA) in China and the FDA in the United States [1] Group 1 - Zhonghui Biotech's stock increased by 7.25%, reaching HKD 50.6, with a trading volume of HKD 13.6446 million [1] - The company announced that its self-developed recombinant respiratory syncytial virus vaccine (CHO cell) has received IND approval from the NMPA and the FDA [1] - The vaccine utilizes CHO cells to express modified pre-F proteins and has shown higher pre-F expression levels, better thermal stability, and superior immunogenicity compared to existing RSV vaccines in preclinical studies [1]
中慧生物-B涨超7% 重组呼吸道合胞病毒疫苗IND申请中美双报获批